Update

RNS Number : 9600H

ValiRx PLC

30 March 2020

 

ValiRx Plc

("ValiRx" or the "Company")

Update

London, UK . 30 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, provides the following update:-

The Company remains critically short of working capital and as previously stated is dependent on the ongoing support of its creditors in order to continue trading.

The Company adjourned its General Meeting which was to be held on 25 March 2020 as a result of the COVID-19 situation.

The Company is reviewing options available to it in order to reconvene the meeting, bearing in mind the current restrictions on public gatherings.

The Company is in discussions with a number of potential funders who have indicated conditional willingness to invest in the Company in the event that resolutions are passed.

There is no guarantee that resolutions will be passed by shareholders at the General Meeting or that funding will ultimately be available to the Company or that creditors will be willing to extend their support to enable potential funding to occur.  A further announcement will be made in due course.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:

ValiRx plc	Tel: [phone] www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: [phone]
Tarquin Edwards, Head of Communications.	Tel: [phone] [e-mail]
Cairn Financial Advisers LLP - Nominated Adviser
Liam Murray / Jo Turner	Tel: [phone]

 

END

 

 

UPDDGGDXXSDDGGC